PHAS - Week In Review: RemeGen Out-Licenses Rights For HER2 ADC To Seagen In $2.6 Billion Deal

• XtalPi, a US-China AI-based drug discovery company, completed a $400 million Series D financing at an estimated valuation of $2 billion.
• Shanghai's HutchMed announced a $310 million deal to acquire greater China rights to Epizyme's epigenetic treatment for niche cancers.
• Advaccine Biopharma Suzhou and Sinovac Biotech will conduct two China trials of Sinovac's approved COVID-19 vaccine combined with US-based Innovio's DNA vaccine candidate for COVID-19.
• PhaseBio Pharma and SFJ Pharma announced their partnered drug, bentracimab, was approved to start a China Phase III trial.

For further details see: